Skip to main content
PMC home page
Nature Portfolio logoLink to Nature Portfolio
. 2023 Nov 3;30(2):607. doi: 10.1038/s41591-023-02661-5

Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

John M Kirkwood 1,✉, Michele Del Vecchio 2, Jeffrey Weber 3, Christoph Hoeller 4, Jean-Jacques Grob 5, Peter Mohr 6, Carmen Loquai 7, Caroline Dutriaux 8, Vanna Chiarion-Sileni 9, Jacek Mackiewicz 10, Piotr Rutkowski 11, Petr Arenberger 12, Gaelle Quereux 13, Tarek M Meniawy 14, Paolo A Ascierto 15, Alexander M Menzies 16, Piyush Durani 17, Maurice Lobo 17, Federico Campigotto 17, Brian Gastman 18,#, Georgina V Long 16,#
PMCID: PMC10878963  PMID: 37923838

Correction to: Nature Medicine 10.1038/s41591-023-02583-2, published online 16 October 2023.

In the version of the article initially published, John M. Kirkwood was presented in the author list without a middle initial. The error has been corrected in the HTML and PDF versions of the article.

Articles from Nature Medicine are provided here courtesy of Nature Publishing Group

RESOURCES